Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GALATIR: BCD-021 vs Lucentis in Wet AMD
NCT02036723Phase 3Withdrawn
- Sponsor
- BIOCAD
- Primary completion
- Mar 2016
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of bevacizumab biosimilar BCD-021 in exudative macular degeneration (2 arms), sponsored by BIOCAD. Primary endpoint: Proportion of patients losing fewer than 15 letters on EDTRS chart at 52 weeks. Status: withdrawn.
02
Drugs
bevacizumab biosimilar BCD-021
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT02036723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02036723.